Cas:2050-14-8 2,2′-dihydroxyazobenzene manufacturer & supplier

Chemical Name:2,2′-dihydroxyazobenzene

CAS.NO:2050-14-8

Synonyms:EINECS 218-082-3;2,2′-Azodiphenol;MFCD00002182;2,2′-Dihydroxyazobenzene ,Mg and other Metals];2,2-Dihydroxyazobenzene;2′-dihydroxyazobenzene

Molecular Formula:C₁₂H₁₀N₂O₂

Molecular Weight:214.22000

HS Code:2927000090

Physical and Chemical Properties:

Melting point:173-175 °C(lit.)

Boiling point:380.4ºC at 760mmHg

Density:1.24g/cm3

Index of Refraction:1.618

PSA:65.18000

Exact Mass:214.07400

LogP:3.51320

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like EINECS 218-082-3 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2′-dihydroxyazobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,2′-Dihydroxyazobenzene ,Mg and other Metals] Use and application,2,2′-Azodiphenol technical grade,usp/ep/jp grade.

Related News: Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2,2′-dihydroxyazobenzene manufacturer Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules. 2,2′-dihydroxyazobenzene supplier Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. 2,2′-dihydroxyazobenzene vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 2,2′-dihydroxyazobenzene factory Genzyme Pharmaceuticals develops and manufactures chemically synthesized pharmaceutical materials and technologies for the global pharmaceutical industry and focuses on lipids, peptides, carbohydrates, oligonucleotides, and custom small molecules.